Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 4Other hematologic neoplasm 3Gastrointestinal 3Tumor-Agnostic 2Lymphoid 2Thoracic 1Sarcoma 1Plasma cell 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cell- and Tissue-Based Therapy × Tumor-Agnostic × Clear all
NCT02193503 2023-09-28

MVX-ONCO-1 in Patients With Solid Tumor

Maxivax SA

Phase 1 Active not recruiting
34 enrolled
Tumor-Agnostic

Neoplasms

NCT00149006 2007-03-14

Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors

Hadassah Medical Organization

Phase 2 Unknown
100 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡